Focus

lecanemab

Dementia & Alzheimer's
Dementia & Alzheimer's

Many Ineligible for New Alzheimer’s Drugs: Study

Many Ineligible for New Alzheimer’s Drugs: Study
|
Dementia & Alzheimer's
Dementia & Alzheimer's

New Case Report Links 1 Death to New FDA-Approved Alzheimer’s Drug

New Case Report Links 1 Death to New FDA-Approved Alzheimer’s Drug
|
Dementia & Alzheimer's
Dementia & Alzheimer's

Alzheimer’s Drug Leqembi Gains FDA Panel’s Support for Full Approval

Alzheimer’s Drug Leqembi Gains FDA Panel’s Support for Full Approval
|
Alzheimer's Disease
Alzheimer's Disease

Lecanemab May Reverse Alzheimer’s Disease, But 3 Deaths Raise Questions

Lecanemab May Reverse Alzheimer’s Disease, But 3 Deaths Raise Questions
|
Health News
Health News

FDA Grants Accelerated Approval for Alzheimer’s Drug Lecanemab

FDA Grants Accelerated Approval for Alzheimer’s Drug Lecanemab
|
Dementia & Alzheimer's
Dementia & Alzheimer's

Many Ineligible for New Alzheimer’s Drugs: Study

Many Ineligible for New Alzheimer’s Drugs: Study
|
Dementia & Alzheimer's
Dementia & Alzheimer's

New Case Report Links 1 Death to New FDA-Approved Alzheimer’s Drug

New Case Report Links 1 Death to New FDA-Approved Alzheimer’s Drug
|
Dementia & Alzheimer's
Dementia & Alzheimer's

Alzheimer’s Drug Leqembi Gains FDA Panel’s Support for Full Approval

Alzheimer’s Drug Leqembi Gains FDA Panel’s Support for Full Approval
|
Alzheimer's Disease
Alzheimer's Disease

Lecanemab May Reverse Alzheimer’s Disease, But 3 Deaths Raise Questions

Lecanemab May Reverse Alzheimer’s Disease, But 3 Deaths Raise Questions
|
Health News
Health News

FDA Grants Accelerated Approval for Alzheimer’s Drug Lecanemab

FDA Grants Accelerated Approval for Alzheimer’s Drug Lecanemab
|